In HCC, a CRISPR-Cas9-based screening revealed that EGFR is synthetic lethal with Lenvatinib, thus blocking of fibroblast growth factor receptor (FGFR), a target of Lenvatinib, leads to upregulation of EGFR (22). Here, EGFR is linked to hepatocellular carcinoma.